Meeting
2022 ASCO Annual Meeting
Ribociclib-induced acute kidney injury: Uncover the MONALEESA’s dark face.
Authors
Maissoune Hajir
King Hussein Cancer Center, Amman, Jordan
Maissoune Hajir , Ramiz Ahmad Abu-Hijlih , Areej Abu Sheikha , Kholoud Alqasem , Hikmat Abdel-Razeq
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1063)
DOI
10.1200/JCO.2022.40.16_suppl.1063
Abstract #
1063
Poster Bd #
441
Abstract Disclosures
Similar Posters
First Author: Peter A. Fasching
Poster
2024 ASCO Annual Meeting
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.
First Author: Sonia Pernas
Poster
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
First Author: Candace Bavette Mainor
Poster
2023 ASCO Annual Meeting
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
First Author: Timothy A. Yap